A Prospective Study of Avatrombopag for Thrombocytopenia Following Hematopoietic Stem Cell Transplantation in Adults with Hematologic Malignancies

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250606003

Enrollment

Registered

2025-06-06

Start date

2025-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Hematologic Malignancy undergoing hematopoietic stem cell transplant Thrombocytopenia Hematopoietic Stem Cell transplantation Hematologic Malignancy

Interventions

Weight based Avatrombopag will be given once daily dose to patients undergoing hematopoietic stem cell transplant starting from day +4 after the first day of stem cell infusion

Experimental Drug

Avatrombopag

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: Adult Patients with Hematologic Malignancy undergoing hematopoietic stem cell transplant

Exclusion criteria

Exclusion criteria: No

Design outcomes

Primary

Measure	Time frame
Platelet engraftment within 30 days after intervention Days from stem cell infusion until sustained platelet count engraftment	—

Secondary

Measure	Time frame
Platelet Transfusion within 30 days after intervention Unit of Platelet	—

Countries

Thailand

Contacts

Public ContactKitsada Wudhikarn

Chulalongkorn University

kitsada.w@chula.ac.th022564000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026